B-cell directed therapies in antiphospholipid antibody syndrome - New directions based on murine and human data

Autoimmunity Reviews

Volumn 11, Issue 10, 2012, Pages 717-722

  Khattri, Saakshi ^a   Zandman Goddard, Gisele ^b   Peeva, Elena ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Anticardiolipin antibody (aCL); Antiphospholipid antibodies (aPL); Antiphospholipid syndrome (APS); Beta 2 Glycoprotein I antibody ( 2GPI); Catastrophic antiphospholipid syndrome (CAPS); Lupus anticoagulant (LAC); Rituximab

Indexed keywords

ABATACEPT; BELIMUMAB; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY;

ANTIBODY TITER; B LYMPHOCYTE; HUMAN; IMMUNOPATHOLOGY; NONHUMAN; PATHOGENESIS; PHOSPHOLIPID ANTIBODY SYNDROME; REVIEW; SYNDROME;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; B-LYMPHOCYTES; BETA 2-GLYCOPROTEIN I; DISEASE MODELS, ANIMAL; HUMANS; MICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864386925     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.12.011     Document Type: Review

References (71)

1. Hanly J.G. Antiphospholipid syndrome: an overview. CMAJ 2003, 168(13):1675-1682.
2. Roubey R.A. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996, 39(9):1444-1454.
3. Pierangeli S.S., Chen P.P., Raschi E., Scurati S., Grossi C., Borghi M.O., et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008, 34(3):236-250.
4. Harris E.N., Pierangeli S.S. Primary, secondary, and catastrophic antiphospholipid syndrome: what's in a name?. Semin Thromb Hemost 2008, 34(3):219-226.
5. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4(2):295-306.
6. Cervera R., Tektonidou M.G., Espinosa G., Cabral A.R., Gonzalez E.B., Erkan D., et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 2011, 20(2):165-173.
7. Cervera R., Tektonidou M.G., Espinosa G., Cabral A.R., Gonzalez E.B., Erkan D., et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus 2011, 20(2):174-181.
8. Cervera R., Bucciarelli S., Espinosa G., Gomez-Puerta J.A., Ramos-Casals M., Shoenfeld Y., et al. Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry"-a tribute to the late Josep Font. Ann N Y Acad Sci 2007, 1108:448-456.
9. Erkan D., Espinosa G., Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010, 10(2):74-79.
10. Espinosa G., Bucciarelli S., Asherson R.A., Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 2008, 34(3):290-294.
11. Bucciarelli S., Espinosa G., Cervera R., Erkan D., Gomez-Puerta J.A., Ramos-Casals M., et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006, 54(8):2568-2576.
12. Espinosa G., Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol 2010, 6(5):296-300.
13. Cervera R., Bucciarelli S., Plasin M.A., Gomez-Puerta J.A., Plaza J., Pons-Estel G., et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun 2009, 32(3-4):240-245.
14. Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 2010, 12(1):70-76.
15. Espinosa G., Berman H., Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011, 10(11):664-668.
16. Hughes G.R., Khamashta M.A. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003, 62(12):1127.
17. Cervera R., Conti F., Doria A., Iaccarino L., Valesini G. Does seronegative antiphospholipid syndrome really exist?. Autoimmun Rev 2012, 11(8):581-584.
18. Pierangeli S.S., Liu S.W., Anderson G., Barker J.H., Harris E.N. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 1996, 94(7):1746-1751.
19. de Groot P.G., Horbach D.A., Derksen R.H. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 1996, 5(5):488-493.
20. Reverter J.C., Tassies D., Font J., Khamashta M.A., Ichikawa K., Cervera R., et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998, 41(8):1420-1427.
21. Meroni P.L. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. J Autoimmun 2008, 30(1-2):99-103.
22. Palatinus A.A., Ahuja K.D., Adams M.J. Effects of antiphospholipid antibodies on in vitro platelet aggregation. Clin Appl Thromb Hemost 2012, 18(1):59-65.
23. Vega-Ostertag M.E., Pierangeli S.S. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep 2007, 9(3):190-197.
24. Jankowski M., Vreys I., Wittevrongel C., Boon D., Vermylen J., Hoylaerts M.F., et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003, 101(1):157-162.
25. Galli M., Borrelli G., Jacobsen E.M., Marfisi R.M., Finazzi G., Marchioli R., et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007, 110(4):1178-1183.
26. Meroni P.L., Gerosa M., Raschi E., Scurati S., Grossi C., Borghi M.O. Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. Clin Rev Allergy Immunol 2008, 34(3):332-337.
27. Blank M., Shoenfeld Y. Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome. Clin Rev Allergy Immunol 2010, 38(2-3):141-147.
28. Rand J.H., Wu X.X., Quinn A.S., Taatjes D.J. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 2010, 19(4):460-469.
29. Horstman L.L., Jy W., Bidot C.J., Ahn Y.S., Kelley R.E., Zivadinov R., et al. Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation 2009, 6:3.
30. Paavonen T., Quartey-Papafio R., Delves P.J., Mackenzie L., Lund T., Youinou P., et al. CD5 mRNA expression and auto-antibody production in early human B cells immortalized by EBV. Scand J Immunol 1990, 31(3):269-274.
31. Velasquillo M.C., Alcocer-Varela J., Alarcon-Segovia D., Cabiedes J., Sanchez-Guerrero J. Some patients with primary antiphospholipid syndrome have increased circulating CD5+ B cells that correlate with levels of IgM antiphospholipid antibodies. Clin Exp Rheumatol 1991, 9(5):501-505.
32. Youinou P., Renaudineau Y. The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb Res 2004, 114(5-6):363-369.
33. Nakken B., Munthe L.A., Konttinen Y.T., Sandberg A.K., Szekanecz Z., Alex P., et al. B-cells and their targeting in rheumatoid arthritis - current concepts and future perspectives. Autoimmun Rev 2011, 11(1):28-34.
34. Miserocchi E., Pontikaki I., Modorati G., Gattinara M., Meroni P.L., Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011, 11(1):35-39.
35. Barcellini W., Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med 2011, 22(3):220-229.
36. Bosello S., De Luca G., Tolusso B., Lama G., Angelucci C., Sica G., et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011, 10(10):624-630.
37. Engel P., Gomez-Puerta J.A., Ramos-Casals M., Lozano F., Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011, 63(1):127-156.
38. Cianciulli T.F., Saccheri M.C., Redruello H.J., Cosarinsky L.A., Celano L., Trila C.S., et al. Right atrial thrombus mimicking myxoma with pulmonary embolism in a patient with systemic lupus erythematosus and secondary antiphospholipid syndrome. Tex Heart Inst J 2008, 35(4):454-457.
39. Weide R., Heymanns J., Pandorf A., Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003, 12(10):779-782.
40. Tomietto P., Gremese E., Tolusso B., Venturini P., De Vita S., Ferraccioli G. B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thromb Haemost 2004, 92(5):1150-1153.
41. Ahn E.R., Lander G., Bidot C.J., Jy W., Ahn Y.S. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am J Hematol 2005, 78(2):127-129.
42. Anandacoomarasamy A., Gibson J., McGill N. 'Cure' of life-threatening antiphospholipid syndrome with rituximab. Intern Med J 2006, 36(7):474-475.
43. Ruckert A., Glimm H., Lubbert M., Grullich C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus 2008, 17(8):757-760.
44. Erre G.L., Pardini S., Faedda R., Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008, 17(1):50-55.
45. Veneri D., Ambrosetti A., Franchini M., Mosna F., Poli G., Pizzolo G. Remission of severe antiphospholipid syndrome associated with non-Hodgkin's B-cell lymphoma after combined treatment with rituximab and chemotherapy. Haematologica 2005, (90 Suppl.):ECR37.
46. Manner H., Jung B., Tonassi L., Hackenberg U., Plum N., Josten K.M., et al. Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. Am J Med Sci 2008, 335(5):394-397.
47. Harner K.C., Jackson L.W., Drabick J.J. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. Rheumatology (Oxford) 2004, 43(10):1309-1310.
48. Iglesias-Jimenez E., Camacho-Lovillo M., Falcon-Neyra D., Lirola-Cruz J., Neth O. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics 2010, 125(6):e1523-e1528.
49. Nageswara Rao A.A., Arteaga G.M., Reed A.M., Gloor J.M., Rodriguez V. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer 2009, 52(4):536-538.
50. Tsagalis G., Psimenou E., Nakopoulou L., Laggouranis A. Effective treatment of antiphospholipid syndrome with plasmapheresis and rituximab. Hippokratia 2010, 14(3):215-216.
51. Adamson R., Sangle S., Kaul A., Hughes G.R., D'Cruz D.P. Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol 2008, 14(6):359-360.
52. van Wissen S., Bastiaansen B.A., Stroobants A.K., van den Dool E.J., Idu M.M., Levi M., et al. Catastrophic antiphospholipid syndrome mimicking a malignant pancreatic tumour-a case report. Lupus 2008, 17(6):586-590.
53. Chalam K.V., Gupta S.K., Agarwal S. Rituximab effectively reverses papilledema associated with cerebral venous sinus thrombosis in antiphospholipid antibody syndrome. Eur J Ophthalmol 2007, 17(5):867-870.
54. Ames P.R., Tommasino C., Fossati G., Scenna G., Brancaccio V., Ferrara F. Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol 2007, 86(3):227-228.
55. Rubenstein E., Arkfeld D.G., Metyas S., Shinada S., Ehresmann S., Liebman H.A. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006, 33(2):355-357.
56. Trappe R., Loew A., Thuss-Patience P., Dorken B., Riess H. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol 2006, 85(2):134-135.
57. Binstadt B.A., Caldas A.M., Turvey S.E., Stone K.D., Weinstein H.J., Jackson J., et al. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr 2003, 143(5):598-604.
58. Erdozain J.G., Ruiz-Irastorza G., Egurbide M.V., Aguirre C. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica 2004, 89(9):ECR34.
59. Asherson R.A., Espinosa G., Menahem S., Yinh J., Bucciarelli S., Bosch X., et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 2008, 37(6):366-372.
60. Sciascia S., Naretto C., Rossi D., Bazzan M., Roccatello D. Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 2011, 20(10):1106-1108.
61. Tincani A., Gilburd B., Abu-Shakra M., Blank M., Allegri F., Ottaviani R., et al. Immunization of naive BALB/c mice with human beta2-glycoprotein I breaks tolerance to the murine molecule. Arthritis Rheum 2002, 46(5):1399-1404.
62. Shoenfeld Y., Ziporen L. Lessons from experimental APS models. Lupus 1998, 7(Suppl. 2):S158-S161.
63. Blank M., Baraam L., Eisenstein M., Fridkin M., Dardik R., Heldman Y., et al. beta2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pGSK3beta expression and reduces experimental-antiphospholipid-syndrome. J Autoimmun 2011, 37(1):8-17.
64. Akkerman A., Huang W., Wang X., Ramanujam M., Schiffer L., Madaio M., et al. CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity 2004, 37(6-7):445-451.
65. Hashimoto Y., Kawamura M., Ichikawa K., Suzuki T., Sumida T., Yoshida S., et al. Anticardiolipin antibodies in NZW×BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 1992, 149(3):1063-1068.
66. Thiagarajan P., Le A., Shapiro S.S. Characterization of beta2-glycoprotein I-dependent and -independent "antiphospholipid" antibodies from lupus-prone NZW/BXSB F1 hybrid male mice. Am J Hematol 1997, 56(2):86-92.
67. Ramanujam M., Davidson A. The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther 2004, 6(5):197-202.
68. Kahn P., Ramanujam M., Bethunaickan R., Huang W., Tao H., Madaio M.P., et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 2008, 58(9):2824-2834.
69. Vianna J.L., Khamashta M.A., Ordi-Ros J., Font J., Cervera R., Lopez-Soto A., et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994, 96(1):3-9.
70. Danowski A., de Azevedo M.N., de Souza Papi J.A., Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009, 36(6):1195-1199.
71. Ramos-Casals M., Brito-Zeron P., Munoz S., Soto M.J. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008, 87(6):345-364.